1. Scrip
  2. >>Therapy Areas

In NASH Race, Bad News For Conatus, Good News For Genfit In PBC

 
• By Joseph Haas

Conatus’ emricasan fails to meet the primary endpoint for portal hypertension in NASH patients with cirrhosis, but firm stresses promising subgroup data. Genfit hits Phase II primary endpoint in PBC with elafibranor, which is also in Phase III for NASH.

female scientist working with microscope

While investors await the initial Phase III data readouts for new drugs in non-alcoholic steatohepatitis (NASH) in 2019, a pair of companies long involved in the race to bring the first NASH therapy to market experienced divergent fates this past week. Conatus Pharmaceuticals Inc. got its second mid-stage setback with NASH candidate emricasan, failing to meet a Phase IIb primary endpoint in portal hypertension, while Genfit SA reported Phase II success with elafibranor in primary biliary cholangitis (PBC).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.